Literature DB >> 9101693

Which antidepressant? A commentary from general practice on evidence-based medicine and health economics.

D P Kernick1.   

Abstract

BACKGROUND: With increasing demand for health care, evidence-based medicine combined with health economics offers a method of optimizing allocation of limited resources. Depression is an illness that has a high prevalence with important medical, social and economic implications. More than 90% of depression is diagnosed and treated in general practice. AIM: To review the effectiveness of an evidence-based approach combined with health economics in deciding whether a tricyclic antidepressant (TCA) or a selective serotonin reuptake inhibitor (SSRI) should be used in the treatment of depression in general practice.
METHOD: An evidence-based strategy tested the two treatments against the criteria of appropriateness, efficacy, effectiveness and value for money.
RESULTS: Although both drugs were equally efficacious, their relative effectiveness and value for money could not be accurately defined.
CONCLUSION: An evidence-based approach does not make clear whether SSRIs or TCAs should be used for the treatment of depression in general practice. Research questions arising from general practice should be addressed in a relevant setting and should yield answers that will complement and support a more pragmatic system of medicine rather than seek to direct it.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101693      PMCID: PMC1312914     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  34 in total

Review 1.  Recognition and management of depression in general practice: consensus statement.

Authors:  E S Paykel; R G Priest
Journal:  BMJ       Date:  1992-11-14

2.  Can meta-analyses be trusted?

Authors:  S G Thompson; S J Pocock
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  Medical practice and the double-blind, randomized controlled trial.

Authors:  B G Charlton
Journal:  Br J Gen Pract       Date:  1991-09       Impact factor: 5.386

4.  Continuation drug therapy for major depressive episodes: how long should it be maintained?

Authors:  R F Prien; D J Kupfer
Journal:  Am J Psychiatry       Date:  1986-01       Impact factor: 18.112

5.  Treatment of pruritus due to chronic obstructive liver disease.

Authors:  J S Duncan; H J Kennedy; D R Triger
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-07

6.  The costs of depression.

Authors:  P Kind; J Sorensen
Journal:  Int Clin Psychopharmacol       Date:  1993-01       Impact factor: 1.659

Review 7.  Depressive disorder in primary care.

Authors:  C V Blacker; A W Clare
Journal:  Br J Psychiatry       Date:  1987-06       Impact factor: 9.319

8.  Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks.

Authors:  A I Scott; C P Freeman
Journal:  BMJ       Date:  1992-04-04

9.  Using the Hospital Anxiety and Depression Scale to screen for psychiatric disorders in people presenting with deliberate self-harm.

Authors:  D Hamer; D Sanjeev; E Butterworth; P Barczak
Journal:  Br J Psychiatry       Date:  1991-06       Impact factor: 9.319

Review 10.  Toxicity of antidepressants: comparisons with fluoxetine.

Authors:  J A Henry
Journal:  Int Clin Psychopharmacol       Date:  1992-06       Impact factor: 1.659

View more
  5 in total

1.  Utility of self-reported sleep disturbances as a marker for major depressive disorder (MDD): findings from the World Mental Health Japan Survey 2002-2006.

Authors:  Shuntaro Ando; Norito Kawakami
Journal:  Psychiatry Res       Date:  2012-02-28       Impact factor: 3.222

2.  General practitioners' perceptions of effective health care.

Authors:  Z Tomlin; C Humphrey; S Rogers
Journal:  BMJ       Date:  1999-06-05

Review 3.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 4.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 5.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.